Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 study titled ‘A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.’ The study aims to evaluate the efficacy and safety of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This study is significant as it explores a potential new treatment option for HS, a painful and chronic inflammatory skin condition.
The intervention being tested is upadacitinib, an oral drug already approved for several inflammatory conditions. It is being assessed for its effectiveness in reducing disease activity and managing adverse events in HS patients.
The study is interventional, with participants randomly assigned to receive either upadacitinib or a placebo. It follows a parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of which treatment participants receive. The primary purpose of the study is treatment-focused.
The study began on June 21, 2023, and is currently recruiting participants. The primary completion date is set for June 24, 2025, which is also the date of the last update submission. These dates are crucial as they indicate the timeline for data collection and potential results dissemination.
This study could have significant market implications for AbbVie, potentially boosting its stock performance if upadacitinib proves effective for HS. It could also impact investor sentiment positively, given the unmet need for effective HS treatments. Competitors in the dermatology and immunology sectors will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.